ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1698

Peripheral Blood Eosinophil Counts Increase in Patients with Systemic Sclerosis and Associated with Its Disease Severity

Tamao Nakashita1, Shinji Motojima2, Katsutoshi Ando3 and Akira Dibatake4, 1Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa City, Japan, 2[email protected], Kameda Medical Center, Kamogawa City, Japan, 3Depertment of Respiratoly Medicine, Juntendo university, tokyo, Japan, 4Rheumatology and Allergy, Kameda Medical Center, Kamogawa city, Japan

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: interstitial lung disease, skin fibrosis and systemic sclerosis

  • Tweet
  • Email
  • Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics: Systemic Sclerosis, Diagnostic and Therapeutic Aspects

Session Type: Abstract Submissions (ACR)

Background/Purpose : Increased levels of serum pro-fibrotic cytokines such as IL-4 and IL-13 and plasma CXCL4 have been previously reported in patients with systemic sclerosis (SSc).  These pro-fibrotic cytokines also play an important role for differentiation and migration of eosinophils and eosinophils themselves release pro-fbrotic cytokines such as IL-11 and TGF-beta.  Accordingly, we hypothesized that eosinophils might contribute, at least partly, to fibrotic process of SSc.

Methods : We retrospectively reviewed the peripheral blood eosinophil counts (PB-EOS) in 70 untreated patients with SSc (diffuse 14, limited 56) and compared with those in other major connective tissue diseases including 126 patients with RA, 10 with PM/DM, 19 with primary Sjögren’s syndrome (SjS), 20 with SLE and 8 with mixed connective tissue disease (MCTD).  The diagnosis was made according to the criteria of ACR, except that criteria used for MCTD was that by Japan Ministry of Health, Labor and Welfare.  All the patients were not on treatment by glucocorticoid and/or immunosuppressant. We also evaluated the association with disease severity of SSc, that is, the grade of interstitial lung disease (ILD) and skin sclerosis.  The severity of ILD was graded into 4, grades 0 to grade 3, according to the extent of ILD on chest CT by the method of Gochuico et al. (Arch Intern Med 2008).  Chest CT images were graded by 2 independent respirologists.  The skin sclerosis was evaluated by modified Rodnan’s skin score (mRodnan SS). 

Results : The mean of coefficient of variance of PB-EOS in 8 patients was 0.32, suggesting that PB-EOS are considerably stable.  The order of mean PB-EOS was as follows; diffuse-SSc (mean 312/mcL) > limited-SSc (210) > PM/DM (164) = RA (154) > pSJS (128) > MCTD (73) = SLE (57) (> indicates significantly different).  ILD was observed in 39 % (27/70) of SSc patients, and the numbers of SSc patients with grade 0/1/2/3 were 43/15/9/3, respectively.  PB-EOS positively correlated with ILD grade in SSc (rs = 0.26, p < 0.02), but not in RA (rs = 0.02) and other diseases. M-Rodnan SS also correlated with PB-EOS (rs = 0.35, p = 0.003) and ILD severity (rs = 0.57, p < 0.0001).  

Conclusion : It was suggested that eosinophils contribute, at least in part, to fibrotic process in SSc and anti-eosinophil strategy might become a treatment option when such drugs become available.  It is also suggested that the mechanism of ILD is somewhat different between SSc and RA. Authors have no COI.


Disclosure:

T. Nakashita,
None;

S. Motojima,
None;

K. Ando,
None;

A. Dibatake,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/peripheral-blood-eosinophil-counts-increase-in-patients-with-systemic-sclerosis-and-associated-with-its-disease-severity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology